Skip to main content
SpringerLink
Log in

Gesundheitsbezogene Lebensqualität (HRQoL)

  • Chapter
  • First Online:
Betaferon®

Zusammenfassung

In klinischen Studien an Patienten mit Multipler Sklerose (MS) wird der Erfolg einer Therapie sehr häufig anhand von jährlicher Schubrate, Expanded Disability Status Scale (EDSS), oder/ und anhand von Aktivitätsparametern in der zerebralen Magnetresonanztomographie bewertet. Diese objektiven Endpunkte liefern wertvolle Information über die bestmögliche Krankheitsbehandlung, erfassen jedoch die Gesamtsituation der Patienten nur sehr ungenügend. Patienten mit MS haben eine eingeschränkte gesundheitsbezogene Lebensqualität (HRQoL). Instrumente, die die Veränderung der HRQoL messen, können die Ergebnisse von klinischen Studien komplementieren und richten den Fokus weg von der Erkrankung hin zu den Betroffenen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 49.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L (2001) Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Multiple Sclerosis 7(5):340–344

    PubMed  CAS  Google Scholar 

  2. Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in early onset multiple sclerosis: a reappraisal after 10 years. Archives of Neurology 58:1602–1606

    Article  PubMed  CAS  Google Scholar 

  3. Archibald CJ, McGrath PJ, Ritvo PG, Maxner CE, Bhan V, Fisk JD et al (1994) Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 58:89–93

    Article  PubMed  CAS  Google Scholar 

  4. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, Weinstock-Guttman B (2005) Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of the Neurological Sciences 231:29–34

    Article  PubMed  Google Scholar 

  5. Benito-Léon J, Morales JM, Rivera-Navarro A, Mitchell AJ (2003) A review about the impact of multiple sclerosis on health-related quality of life. Disability and Rehabilitation 25:1291–1303

    Article  PubMed  Google Scholar 

  6. Bergner M, Bobbitt RA, Carter WB, Gilson BS (1981) The Sickness Impact Profile: development and final revision of a health status measure. Medical Care 19:787–805

    Article  PubMed  CAS  Google Scholar 

  7. Boylan LS, Flint LA, Labovitz DL, Jackson SC, Starner K, Devinsky O (2004) Depression but not seizure frequency predicts quality of life in treatment resistant epilepsy. Neurology 62:258–261

    Article  PubMed  CAS  Google Scholar 

  8. Brownscombe I, Laupacis A, Rice GPA, Ebers GC, Noseworthy JH (1990) Development of a disease-specific quality-of-life measure for multiple sclerosis. Neurology 40:142

    Google Scholar 

  9. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, Chang C, Lloyd S, Steward J, Stefoski D (1996) Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47:129–139

    Article  PubMed  CAS  Google Scholar 

  10. Cella D, Nowinski C, Peterman A, Victorson D, Miller D, Lai JS, Moy C (2011) The Neurology Quality of Life Measurement Initiative. Archives of Physical Medicine and Rehabilitation 92(10):28–36

    Article  Google Scholar 

  11. Cella D, Lai JS, Nowinski CJ, Victorson D, Peterman A, Miller D, Bethoux F, Heinemann A, Rubin S, Cavazos JE, Reder AT, Sufit R, Simuni T, Holmes GL, Siderowf A, Wojna V, Bode R, McKinney N, Podrabsky T, Wortman K, Choi S, Gershon R, Rothrock N, Moy C (2012) Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology 78(23):1860–1867

    Article  PubMed  CAS  Google Scholar 

  12. Charcot JM (1877) Lectures on the diseases of the central nervous system delivered at the Salpetriere. New Sydenham Society London, pp 194–195

    Google Scholar 

  13. Costelloe L, O’Rourke K, Kearney H, McGuigan C, Gribbin L, Duggan M, Daly L, Tubridy N, Hutchinson M (2007) The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). Journal of Neurology, Neurosurgery 78:841–844

    Article  Google Scholar 

  14. Cutajar R, Ferriani E, Scandellari C, Sabattini L, Trocino C, Marchello LP, Stecchi S (2000) Cognitive function and quality of life in multiple sclerosis patients. Journal of Neurovirology 6:186–190

    Google Scholar 

  15. Devins GM, Edworthy SM, Seland TP, Klein GM, Paul LC, Mandin H (1993) Differences in illness intrusiveness across rheumatoid arthritis, end-stage renal disease, and multiple sclerosis. Journal of Nervous and Mental Disease 181:377–381

    Article  PubMed  CAS  Google Scholar 

  16. Ebers GC (2005) Prognostic factors for multiple sclerosis: the importance of natural history studies. Journal of Neurology 252(3):iii15–iii20 ((suppl 3))

    PubMed  Google Scholar 

  17. Ehde DM, Gibbons LE, Chwastiak L, Bombardier CH, Sullivan MD, Kraft GH (2003) Chronic pain in a large community sample of persons with multiple sclerosis. Multiple Sclerosis 9:605–611

    Article  PubMed  Google Scholar 

  18. EuroQoL Group (1990) EuroQoL − a new facility for the measurement of health-related quality of life. Health Policy 16:199–208

    Article  Google Scholar 

  19. European Study Group on Interferon-b in Secondary Progressive Multiple Sclerosis (1998) Placebo-controlled multi-center randomized trial of interferon 1-b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491–1497

    Article  Google Scholar 

  20. Freeman J, Langdon DW, Hobart JC, Thompson AJ (1996) Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation. Journal of Neurolic Rehabilitation 10:185–194

    Google Scholar 

  21. Fruehwald S, Loeffler-Stastka H, Eher R, Saletu B, Baumhackl U (2001) Depression and quality of life in multiple sclerosis. Acta Neurologica Scandinavica 104(5):257–261

    Article  PubMed  CAS  Google Scholar 

  22. Gold SM, Heesen C, Schulz H, Guder U, Mönch A, Gbadamosi J, Buhmann C, Schulz KH (2001) Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Multiple Sclerosis 7(2):119–130

    PubMed  CAS  Google Scholar 

  23. Gold SM, Schulz H, Monch A, Schulz KH, Heesen C (2003) Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Multiple Sclerosis 9:404–410

    Article  PubMed  Google Scholar 

  24. Hakim EA, Bakheit AM, Bryant TN, Roberts MW, McIntosh-Michaelis SA, Spackman AJ, Martin JP, McLellan DL (2000) The social impact of multiple sclerosis: a study of 305 patients and their relatives. Disability and Rehabilitation 22:288–293

    Article  PubMed  CAS  Google Scholar 

  25. Hemmett L, Holmes J, Barnes M, Russell N (2004) What drives quality of life in multiple sclerosis? QJM 97(10):671–676

    Article  PubMed  CAS  Google Scholar 

  26. Henriksson F, Fredrikson S, Masterman T, Jonsson B (2001) Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. European Journal of Neurology 8(1):27–35

    Article  PubMed  CAS  Google Scholar 

  27. Hermann BP, Vickrey B, Hays RD, Cramer J, Devinsky O, Meador K, Perrine K, Myers LW, Ellison GW (1996) A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Research 25:113–118

    Article  PubMed  CAS  Google Scholar 

  28. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A (2001) The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 124:962–973

    Article  PubMed  CAS  Google Scholar 

  29. Janardhan V, Bakshi R (2002) Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. Journal of Neurolical Sciences 205:51–58

    Article  Google Scholar 

  30. Jonsson A, Dock J, Ravnborg MH (1996) Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis. Acta Neurologica Scandinavica 93:229–235

    Article  PubMed  CAS  Google Scholar 

  31. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 31(67):1242–1249

    Article  Google Scholar 

  32. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370:389–397

    Article  PubMed  CAS  Google Scholar 

  33. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C for the BENEFIT Study Group (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology 8:987–997

    Article  PubMed  CAS  Google Scholar 

  34. Kassirer M (2000) Multiple sclerosis and pain: a medical focus. International Journal of MS Care 2:30–34

    Article  Google Scholar 

  35. Kauhanen ML, Korpelainen JT, Hiltunen P, Nieminen P, Sotaniemi KA, Myllylä VV (2000) Domains and determinants of quality of life after stroke caused by brain infarction. Archives of Physical Medicine and Rehabilitation 81:1541–1546

    Article  PubMed  CAS  Google Scholar 

  36. Kobelt G, Jönsson L, Fredrikson S (2003) Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. European Journal of Health Economics 4(1):50–59

    Article  PubMed  CAS  Google Scholar 

  37. Kreuter M, Sullivan M, Dahllof AG, Siosteen A (1998) Partner relationships, functioning, mood and global quality of life in persons with spinal cord injury and traumatic brain injury. Spinal Cord 37(36):252–261

    Article  Google Scholar 

  38. Krupp L (2006) Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Multiple Sclerosis 12(4):367–368

    Article  PubMed  Google Scholar 

  39. Lou JS, Reeves A, Benice T, Sexton G (2003) Fatigue and depression are associated with poor quality of life in ALS. Neurology 60:122–123

    Article  PubMed  Google Scholar 

  40. McCabe MP, McKern S (2002) Quality of life and multiple sclerosis: Comparison between people with multiple sclerosis and people from the general population. Journal of Clinical Psychology in Medical Settings 9:287–295

    Article  Google Scholar 

  41. Mitchell AJ, Benito-León J, González JM, Rivera-Navarro J (2005) Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurology 4(9):556–566

    Article  PubMed  Google Scholar 

  42. Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A (2009) A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Multiple Sclerosis 15(10):1195–1205

    Article  PubMed  CAS  Google Scholar 

  43. Morales-Gonzalez JM, Benito-LeoÏn J, Rivera-Navarro J, Mitchell AJ (2004) A systematic approach to analyze health-related quality of life in multiple sclerosis: the GEDMA study. Multiple Sclerosis 10:47–54

    Article  Google Scholar 

  44. North American Study Group on Interferon beta-b in Secondary Progressive MS (2004) Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63:1788–1795

    Article  Google Scholar 

  45. Nortvedt MW, Riise T, Myhr KM, Nyland HI (1999) Quality of life in multiple sclerosis – Measuring the disease effects more broadly. Neurology 53:1098–1103

    Article  PubMed  CAS  Google Scholar 

  46. Nortvedt MW, Riise T, Myhr KM, Nyland HI (2000) Quality of life as a predictor for change in disability in MS. Neurology 55:51–54

    Article  PubMed  CAS  Google Scholar 

  47. Nortvedt MV, Riise T (2003) The use of quality of life measures in multiple sclerosis research. Multiple Sclerosis 9:63–72

    Article  PubMed  CAS  Google Scholar 

  48. O’Connor P, Lee L, Ng PT, Narayana P, Wolinsky JS (2001) Determinants of overall quality of life in secondary progressive MS: a longitudinal study. Neurology 57(5):889–891

    Article  PubMed  Google Scholar 

  49. Pelletier G, Verhoef MJ, Khatri N, Hagen N (2002) Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncology 57:41–49

    Article  Google Scholar 

  50. Pfennings L, Cohen L, Adèr H, Polman C, Lankhorst G, Smits R, van der Ploeg H (1999) Exploring differences between subgroups of multiple sclerosis patients in health-related quality of life. Journal of Neurology 246:587–591

    Article  PubMed  CAS  Google Scholar 

  51. Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M (2004) Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study. Archives of Neurology 61:679–686

    Article  PubMed  Google Scholar 

  52. Plosker GL (2011) Interferon-β-1b: a review of its use in multiple sclerosis. CNS Drugs 25(1):67–88

    Article  PubMed  CAS  Google Scholar 

  53. Pozzilli C, Schweikert B, Ecari U, Oentrich W, Bugge JP (2012) Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. Journal of Neurology 259(11):2319–2328

    Article  PubMed  Google Scholar 

  54. Rice GP, Oger J, Duquette P, Francis GS, Bélanger M, Laplante S, Grenier JF (1999) Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Canadian Journal of Neurological Sciences 26:276–282

    PubMed  CAS  Google Scholar 

  55. Ritvo P, Fischer JS, Miller DM, Andrews H, Paty DW, La-Rocca NG (1997) MSQLI – Multiple Sclerosis Quality of Life Inventory. A user’s manual. National MS Society, New York

    Google Scholar 

  56. Rothwell PM, McDowell Z, Wong CK, Dorman PJ (1997) Doctors and patients don’t agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis. BMJ 314(7094):1580–1583

    Article  PubMed  CAS  Google Scholar 

  57. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG (1992) Quality of life in multiple sclerosis: comparison with inflammatory bowel disease and rheumatoid arthritis. Archives of Neurology 49:1237–1242

    Article  PubMed  CAS  Google Scholar 

  58. Schipper H, Clinch JJ, Olweny CLM (1996) Quality of life studies: definitions and conceptual issues. In: Spilker B (Hrsg) Quality of Life and Pharmacoeconomics in Clinical Trials, 2. Aufl. Lippincott-Raven, Philadelphia, S 11–23

    Google Scholar 

  59. Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T (1997) The quality-of-life effects of interferon beta-1b in multiple sclerosis: an extended Q-TWIST analysis. Archives of Neurology 54:1475–1480

    Article  PubMed  CAS  Google Scholar 

  60. Siegrist J, Junge A (1989) Conceptual and methodological problems in research on the quality of life in clinical medicine. Social Science 29:463–468

    CAS  Google Scholar 

  61. Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N, O’Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S, Ammoury N, Beresniak A, Pelletier J (2008) Validation of the Multiple Sclerosis International Quality of Life questionnaire. Multiple Sclerosis 14(2):219–230

    Article  PubMed  Google Scholar 

  62. Solari A, Filippini G, Mendozzi L, Ghezzi A, Cifani S, Barbieri E, Baldini S, Salmaggi A, Mantia LL, Farinotti M, Caputo D, Mosconi P (1999) Validation of Italian multiple sclerosis quality of life 54 questionnaire. Journal of Neurology, Neurosurgery 67:158–162

    Article  CAS  Google Scholar 

  63. Solari A, Radice D (2001) Health status of people with multiple sclerosis: a community mail survey. Neurol Science 22:307–315

    Article  CAS  Google Scholar 

  64. Somerset M, Campbell R, Sharp DJ, Peters TJ (2001) What do people with MS want and expect from health-care services? Health Expect 4:29–37

    Article  PubMed  CAS  Google Scholar 

  65. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA (2010) Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clinical Drug Investigation 30(2):89–100

    Article  PubMed  CAS  Google Scholar 

  66. The Canadian Burden of Illness Study Group (1998) Burden of illness of multiple sclerosis: Part II: Quality of life. Canadian Journal of Neurological Sciences 25:31–38

    Google Scholar 

  67. The WHOQOL-Group (1994) The development of the World Health Organization quality of life assessment instrument: The WHOQOL. In: Orley J, Kuyken W (Hrsg) Quality of life assessment: International perspectives. Springer, Berlin, Heidelberg, New York, S 41–57

    Chapter  Google Scholar 

  68. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry Patient- Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available at: http://www.fda.gov/CDER/GUIDANCE/5460dft.pdf; 2006. Accessed October 9, 2008.

    Google Scholar 

  69. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW (1995) A health-related quality of life measure for multiple sclerosis. Quality of Life Research 4:187–206

    Article  PubMed  CAS  Google Scholar 

  70. Visschedijk MA, Uitdehaag BM, Klein M, van der Ploeg E, Collette EH, Vleugels L, Pfennings LE, Hoogervorst EL, van der Ploeg HM, Polman CH (2004) Value of health-related quality of life to predict disability course in multiple sclerosis. Neurology 63(11):2046–2050

    Article  PubMed  CAS  Google Scholar 

  71. Wang JL, Reimer MA, Metz LM, Patten SB (2000) Major depression and quality of life in individuals with multiple sclerosis. International Journal of Psychiatry Medicine 30(4):309–317

    CAS  Google Scholar 

  72. Wang SJ, Fuh JL, Lu SR, Juang KD (2001) Quality of life differs among headache diagnoses: analysis of SF-36 survey in 901 headache patients. Pain 89:285–292

    Article  PubMed  CAS  Google Scholar 

  73. Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Medical Care 30:473–483

    Article  PubMed  Google Scholar 

  74. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276(15):1253–1258

    Article  PubMed  CAS  Google Scholar 

  75. Weinstein MC, Skinner JA (2010) Comparative effectiveness and health care spending-implications for reform. New England Journal of Medicine 362(5):460–465

    Article  PubMed  CAS  Google Scholar 

  76. Yeager SL, Marsh L, O’Hearn E, Bassett SS (2004) A comparison of the influence of the diagnosis of depression vs. depressive symptomatology on quality of life on Parkinson’s disease patients. Biological Psychiatry 55:845 ((suppl 8))

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Reha Zentrum Münster, Klinikum für Neurologische Rehabilitation, Gröben 700, 6232, Münster, Österreich

    Rainer Ehling OA Dr.

Authors
  1. Rainer Ehling OA Dr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rainer Ehling OA Dr. .

Editor information

Editors and Affiliations

  1. Medizinische Universität Innsbruck Universitätsklinik für Neurologie, Innsbruck, Austria

    Thomas Berger

  2. Leitender Arzt Klinik für Neurologie, Universitätsspital Zürich, Zürich, Switzerland

    Michael Linnebank

  3. Klinik für Allgemeine Neurologie, Universitätsklinikum Münster, Münster, Germany

    Heinz Wiendl

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Wien

About this chapter

Cite this chapter

Ehling, R. (2013). Gesundheitsbezogene Lebensqualität (HRQoL). In: Berger, T., Linnebank, M., Wiendl, H. (eds) Betaferon®. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1766-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1766-8_14

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1765-1

  • Online ISBN: 978-3-7091-1766-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation